Quantum BioPharma Ltd. Ordinary Shares - Class B (Sub Voting) QNTM 深 沪
已收盘 12-19 16:00:00 美东时间
8.89
+0.070
+0.79%
华盛通- 最 高8.9999
- 今 开8.80
- 成交量 4.65万股
- 最 低 8.45
- 昨 收 8.82
- 总市值 3393.22万
- 52周最高 38.25
- 市盈率 静 --
- 换手率 1.22%
- 52周最低 2.89
- 委 比 -4.76%
- 总股本 381.69万
- 历史最高 909.5234
- 量 比 0.92
- 振 幅 6.23%
- 历史最低 2.89
- 每 手 1
- 风险率 6.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Quantum BioPharma To Broadcast Three-Part Series About Allegations Of Stock Market Manipulation Against Company
Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma"), is pleased to announce that national television network CTV News' flagship investigative program W5 will air, starting today, a
11-26 05:02
Quantum BioPharma Q3 EPS $(1.25) Misses $(0.08) Estimate
Quantum BioPharma (NASDAQ:QNTM) reported quarterly losses of $(1.25) per share which missed the analyst consensus estimate of $(0.08) by 1462.5 percent. This is a 71.4 percent increase over losses of $(4.37) per share
11-07 21:47
Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication
Quantum BioPharma’s licensee, Unbuzzd Wellness, announces a Reg D 506(c) offering targeting $5 million to expand distribution and retail sales of its hangover-relief beverage, unbuzzd. An investor webinar on Oct 30, 2025, will discuss the investment opportunity, leadership, and growth strategy. Unbuzzd, scientifically proven to accelerate alcohol metabolism and reduce hangover symptoms, has gained traction due to its innovation and market relevan...
10-23 12:15
Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend
Quantum BioPharma Ltd. announced the expiration of 53,147 warrants issued to hedge funds and investment funds as part of a 2020 financing. The company reaffirmed October 27, 2025, as the record date for distributing Contingent Value Rights (CVRs) to Class B Subordinate Voting Shareholders. Each CVR entitles holders to a portion of net proceeds from ongoing litigation against financial institutions, seeking over $700 million in damages for alleged...
10-20 12:30
Quantum BioPharma Denies Unsubstantiated Securities Investigation Allegations, Vows Legal Action Against Law Firms
Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech
10-14 20:25
Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case
Quantum BioPharma Ltd. announced that October 27, 2025, will be the record date for distributing contingent value rights (CVRs) to holders of its Class B Subordinate Voting Shares. Each CVR entitles the holder to a pro rata portion of 10% to 50% of the net proceeds from its ongoing litigation against CIBC World Markets, RBC Dominion Securities, and others, which seeks damages exceeding USD $700 million. Payments under CVRs are contingent on recei...
10-03 11:00
Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial
Quantum BioPharma Ltd. announced receipt of two final reports for its Lucid-MS drug targeting Multiple Sclerosis, advancing its IND application for a phase-2 clinical trial. The company expressed excitement over the potential of Lucid-MS to address demyelination in MS.
10-02 11:57
Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials
Quantum BioPharma Ltd. has appointed Dr. Jack Antel, a world-renowned multiple sclerosis (MS) expert, as a clinical advisor for its Lucid-MS program, a drug aimed at inhibiting demyelination in MS. Dr. Antel will advise on the clinical development of Lucid-MS, including designing efficacy trials. His extensive expertise in MS research and his interdisciplinary experience are expected to significantly advance the drug's progress toward a Phase 2 c...
10-01 11:50
Quantum BioPharma Announces Shareholder Meeting Results
The latest update is out from Quantum Biopharma ( ($TSE:QNTM) ). On September 2...
09-29 19:57
Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders
Quantum BioPharma Ltd. announced the results of its annual general and special meeting of shareholders held on September 26, 2025. All nominated directors were elected with over 99% support. Shareholders reappointed MNP LLP as the Company’s auditor and approved the issuance of up to 56 additional Class A Multiple Voting Shares, with 90.992% voting in favor.
09-29 11:40
